CCS
GHDX

Crosspoint Capital Strategies’s Genomic Health, Inc. GHDX Stock Holding History

Crosspoint Capital Strategies’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.32M Buy
+18,815
New +$1.4M 2.38% 29

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Crosspoint Capital Strategies's GHDX Position: Q1 2019 in Review

Crosspoint Capital Strategies opened a new position in Genomic Health, Inc. (GHDX) in Q1 2019: 18,815 shares worth $1.32M. The stake represents 2.38% of the portfolio and ranks #29 among its holdings.

267 funds tracked by Wall St. Rank hold GHDX as of Q1 2019.

  • Crosspoint Capital Strategies held 18,815 shares of Genomic Health, Inc. worth $1.32M as of Q1 2019.
  • Genomic Health, Inc. was a new Crosspoint Capital Strategies position in Q1 2019.
  • Genomic Health, Inc. made up 2.38% of Crosspoint Capital Strategies's portfolio in Q1 2019, its #29 holding.
  • 267 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2019.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2019, filed 13 May 2019.